Abstract
Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.
Owner only: item control page
UR Home
MGMT gene silencing and benefit from temozolomide in glioblastoma
Altmetric
AltmetricMore literature (via CORE)
University Library
Publication Server
Contact:
Publishing: oa@ur.de
0941 943 -4239 or -69394
Dissertations: dissertationen@ur.de
0941 943 -3904
Research data: daten@ur.de
0941 943 -5707